The Incidence of Cognitive Impairment in Cohorts with longitudinal Evaluation – PD

https://neurodegenerationresearch.eu/it/cohort/the-incidence-of-cognitive-impairment-in-cohorts-with-longitudinal-evaluation-%c2%96-pd/

Cohort Acronym
ICICLE-PD

Cohort type
Neurodegenerative disease-specific cohort

Disease
Mild cognitive impairment (MCI), Parkinson's disease, Subjective memory complaints (SMC) or subjective cognitive decline (SCD)

Participant type
Condition diagnosed

Profile
Recruitment Period Jun 09-Mar12
Sample size at start or planned sample size if still recruiting 318
Estimated Current Sample Size 0 to 4,999
Age at Recruitment >18
Gender Male and Female
Abstract

The ICICLE-PD study aims to accurately characterise two independent cohorts of incident parkinsonism in Newcastle-Gateshead and Cambridgeshire. A key objective is to identify patients who develop Parkinson's disease dementia (PDD) and the factors that predict its evolution. From this information, a simplified panel of tests that can be used to predict PDD will be established. ICICLE-PD will therefore provide a platform for studies investigating agents designed to help treat this complication of PD. Participants were recruited between June 2009 and March 2012. Longitudinal follow up is on going with assessments in person at 18-month intervals.

Last update: 16/01/2017

Country United Kingdom
Contact details
Institution name Newcastle University
Website http://www.ncl.ac.uk/caru/about
Principal Investiator (PI) Professor David Burn
Contact email Alison Yarnall Email: alison.yarnall@ncl.ac.uk and Rachel Lawson Email: : rachael.lawson@ncl.ac.uk
Contact phone number +44 (0)191 2081279 and +44 (0) 191 2081277

Funders (Core support) Parkinson's Disease Society
Rhoda Lockhart Parkinson's Disease Research Fund

Variables Collected

Brain related measures:
Cognitive function, Mental health, Neurological
Funtional rating:
Caregiver, Individual physiological
Anthropometric:
Blood pressure, Height, Hip circumference, Waist circumference, Weight
Physical:
Cardiovascular, Hearing and Vision
Biological samples:
Blood, Cerebral spinal fluid (CSF), CSF biomarker data available
Genotyping:
Gene screening
Brain imaging:
Magnetic resonance imaging (MRI), Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)
Brain banking:
Consent for brain donation
Lifestyle:
Alcohol, Physical activity, Smoking
Socio-economic:
Education, Housing and accommodation, Marital status, Occupation and employment, Unpaid care
Health service utilisation:
N/A